The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development ...
Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...
Halo Whippany site Halo Pharma is expanding its manufacturing capabilities at its Whippany, NJ, facility with the addition of ...
"Investing in the Macro-Pactor reinforces Halo Pharma's commitment to delivering high-quality, scalable manufacturing solutions for our clients. It ensures that they can confidently advance their ...
Technological advancements in synthetic chemistry, bioproduction, and containment are enhancing the feasibility of developing ...
The S&P SmallCap 600 underperformed the Russell 2000 by 9% YTD, putting it on track to record its worst year of relative performance since its launch in October 1994. The S&P SmallCap 600’s relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback